MRI visual rating scales in the diagnosis of dementia: ev
confirmed cases

Citation Report

#	Article	IF	Citations
1	Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget, 2016, 7, 38999-39016.	0.8	56
2	Diagnostic Accuracy of MRI andÂAdditional [18F]FDG-PET forÂBehavioral Variant Frontotemporal Dementia in Patients withÂLate Onset Behavioral Changes. Journal of Alzheimer's Disease, 2016, 53, 1287-1297.	1.2	58
3	MRI biomarkers â€" a precision medicine tool in neurology?. Nature Reviews Neurology, 2016, 12, 323-324.	4.9	8
4	Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers. Dementia and Geriatric Cognitive Disorders, 2016, 42, 80-92.	0.7	30
6	Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimerâ€™s disease: Validation in a large memory clinic population. European Radiology, 2017, 27, 3147-3155.	2.3	48
7	Evaluation and clinical correlation of practical cut-offs for visual rating scales of atrophy: normal aging versus mild cognitive impairment and Alzheimerâ€™s disease. Acta Neurologica Belgica, 2017, 117, 661-669.	0.5	9
8	Distinct subtypes of Alzheimerâ€™s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Scientific Reports, 2017, 7, 46263.	1.6	141
9	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 908-916.	0.9	78
10	Imaging and fluid biomarkers in frontotemporal dementia. Nature Reviews Neurology, 2017, 13, 406-419.	4.9	163
11	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
12	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	1.5	60
13	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Into Imaging, 2017, 8, 79-90.	1.6	67
14	Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2017, 44, 45-54.	0.7	10
15	Quantification of brain cholinergic denervation in Alzheimerâ€™s disease using PET imaging with [18F]-FEOBV. Molecular Psychiatry, 2017, 22, 1531-1538.	4.1	126
16	Independent Component Analysis-Support Vector Machine-Based Computer-Aided Diagnosis System for Alzheimerâ€™s with Visual Support. International Journal of Neural Systems, 2017, 27, 1650050.	3.2	74
18	Multi-view visual saliency-based MRI classification for alzheimer's disease diagnosis. , 2017, , .		4
19	Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ: British Medical Journal, 2017, 357, j2353.	2.4	279
20	Classification of Alzheimerâ€™s disease and Parkinsonâ€™s disease usingÂa support vector machine and probabilistic outputs. Chem-Bio Informatics Journal, 2017, 17, 112-124.	0.1	0

#	ARTICLE	IF	CITATIONS
21	Automatic MRI Quantifying Methods in Behavioral-Variant Frontotemporal Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 51-59.	0.6	19
22	Diagnosis of Frontotemporal Dementia. , 2018, , 113-121.		0
23	Semantic dementia and the left and right temporal lobes. Cortex, 2018, 107, 188-203.	1.1	82
24	Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin. Journal of Alzheimer's Disease, 2018, 62, 1113-1123.	1.2	29
25	6 .Diagnostische Methoden. , 2018, , 187-352.		0
26	Prediction of Autopsy Verified Neuropathological Change of Alzheimer's Disease Using Machine Learning and MRI. Frontiers in Aging Neuroscience, 2018, 10, 406.	1.7	26
27	Voxel-wise deviations from healthy aging for the detection of region-specific atrophy. NeuroImage: Clinical, 2018, 20, 851-860.	1.4	18
28	Morphometric MRI as a diagnostic biomarker of frontotemporal dementia: A systematic review to determine clinical applicability. NeuroImage: Clinical, 2018, 20, 685-696.	1.4	32
29	Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease, 2018, 62, 1091-1111.	1.2	228
30	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
32	MRI of non-Alzheimer's dementia: current and emerging knowledge. Current Opinion in Neurology, 2018, 31, 405-414.	1.8	10
33	Automatic normative quantification of brain tissue volume to support the diagnosis of dementia: A clinical evaluation of diagnostic accuracy. NeuroImage: Clinical, 2018, 20, 374-379.	1.4	25
34	The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. Scientific Reports, 2018, 8, 8431.	1.6	55
35	Neuroimaging in Lewy body dementia. Journal of Neurology, 2019, 266, 1-26.	1.8	45
36	The quantitative neuroradiology initiative framework: application to dementia. British Journal of Radiology, 2019, 92, 20190365.	1.0	32
37	The current status of blood epigenetic biomarkers for dementia. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 435-457.	2.7	21
38	Medial temporal lobe atrophy and posterior atrophy scales normative values. NeuroImage: Clinical, 2019, 24, 101936.	1.4	12
39	Characteristic asymmetric limbic and anterior temporal atrophy in demented patients with pathologically confirmed argyrophilic grain disease. Neuroradiology, 2019, 61, 1239-1249.	1.1	15

#	Article	IF	Citations
40	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. Frontiers in Neuroscience, 2019, 13, 757.	1.4	22
41	A Systematic Review and Implementation of IoT-Based Pervasive Sensor-Enabled Tracking System for Dementia Patients. Journal of Medical Systems, 2019, 43, 287.	2.2	35
42	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. NeuroImage: Clinical, 2019, 23, 101927.	1.4	29
43	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.5	51
44	Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 169-178.	1.2	28
45	Diagnosis and Management of Dementia: Review. JAMA - Journal of the American Medical Association, 2019, 322, 1589.	3.8	675
46	Multifaceted structural magnetic resonance imaging findings in demented patients with pathologically confirmed TDP-43 proteinopathy. Neuroradiology, 2019, 61, 1333-1339.	1.1	5
47	PD and DLB: Brain imaging in Parkinson's disease and dementia with Lewy bodies. Progress in Molecular Biology and Translational Science, 2019, 165, 167-185.	0.9	7
48	Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 2019, 14, 5.	4.4	203
49	Naming and conceptual understanding in frontotemporal dementia. Cortex, 2019, 120, 22-35.	1.1	19
50	Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers. Frontiers in Neuroscience, 2019, 13, 658.	1.4	10
51	Multiple Visual Rating Scales Based on Structural MRI and a Novel Prediction Model Combining Visual Rating Scales and Age Stratification in the Diagnosis of Alzheimer's Disease in the Chinese Population. Frontiers in Neurology, 2019, 10, 93.	1.1	13
52	Dementia with Lewy bodies: Challenges in the diagnosis and management. Australian and New Zealand Journal of Psychiatry, 2019, 53, 291-303.	1.3	28
53	Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. Neuroradiology, 2019, 61, 633-642.	1.1	50
54	Predicting cognitive resilience from midlife lifestyle and multi-modal MRI: A 30-year prospective cohort study. PLoS ONE, 2019, 14, e0211273.	1.1	9
55	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2019, 68, 591-608.	1.2	7
56	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. Clinical and Translational Imaging, 2019, 7, 83-98.	1.1	1
57	Diagnostic accuracy of frontotemporal dementia. An artificial intelligence-powered study of symptoms, imaging and clinical judgement. Advances in Medical Sciences, 2019, 64, 292-302.	0.9	9

#	Article	IF	Citations
58	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	2.3	23
59	Detecting frontotemporal dementia syndromes using MRI biomarkers. NeuroImage: Clinical, 2019, 22, 101711.	1.4	35
60	Identifying brain changes related to cognitive aging using VBM and visual rating scales. NeuroImage: Clinical, 2019, 22, 101697.	1.4	10
62	Magnetic resonance imaging brain atrophy assessment in primary age-related tauopathy (PART). Acta Neuropathologica Communications, 2019, 7, 204.	2.4	25
63	Neuroimaging and Machine Learning for Dementia Diagnosis: Recent Advancements and Future Prospects. IEEE Reviews in Biomedical Engineering, 2019, 12, 19-33.	13.1	76
64	Structural and Functional Magnetic Resonance Imaging of Dementia With Lewy Bodies. International Review of Neurobiology, 2019, 144, 95-141.	0.9	8
65	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's and Dementia, 2019, 15, 400-409.	0.4	60
66	MRI-based evaluation of structural degeneration in the ageing brain: Pathophysiology and assessment. Ageing Research Reviews, 2019, 49, 67-82.	5.0	41
67	Domain-specific cognitive effects of white matter pathology in old age, mild cognitive impairment and Alzheimer's disease. Aging, Neuropsychology, and Cognition, 2020, 27, 453-470.	0.7	11
68	Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia. American Journal of Geriatric Psychiatry, 2020, 28, 755-763.	0.6	19
69	Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage. Alzheimer's Research and Therapy, 2020, 12, 120.	3.0	17
70	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102453.	1.4	11
71	Structural imaging in dementia with Lewy bodies: the potential of multivariate data analysis. Psychiatry Research - Neuroimaging, 2020, 306, 111180.	0.9	5
72	Autonomic function in amnestic and non-amnestic mild cognitive impairment: spectral heart rate variability analysis provides evidence for a brain–heart axis. Scientific Reports, 2020, 10, 11661.	1.6	27
73	Magnetic Resonance Imaging in Stable Mild Cognitive Impairment, Prodromal Alzheimer's Disease, and Prodromal Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2020, 49, 583-588.	0.7	8
74	Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. Annals of Internal Medicine, 2020, 172, 669-677.	2.0	25
75	Structural brain imaging as a diagnostic tool in dementia, why and how?. Psychiatry Research - Neuroimaging, 2020, 306, 111183.	0.9	9
76	Evaluation of Ultrafast Wave-CAIPI MPRAGE for Visual Grading and Automated Measurement of Brain Tissue Volume. American Journal of Neuroradiology, 2020, 41, 1388-1396.	1.2	33

#	Article	IF	Citations
77	Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnestic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts. Journal of Alzheimer's Disease, 2020, 77, 323-337.	1.2	9
78	The Entorhinal Cortex Atrophy Score Is Diagnostic and Prognostic in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 75, 99-108.	1.2	10
79	What to make of equivocal amyloid imaging results. Neurocase, 2020, 26, 137-146.	0.2	2
80	Creation of an anthropomorphic CT head phantom for verification of image segmentation. Medical Physics, 2020, 47, 2380-2391.	1.6	10
81	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	3.7	158
82	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 1575-1583.	1.2	12
83	Normative brain volume reports may improve differential diagnosis of dementing neurodegenerative diseases in clinical practice. European Radiology, 2020, 30, 2821-2829.	2.3	27
84	University College London/University of Gothenburg PhD course â€œBiomarkers in neurodegenerative diseasesâ€•2019â€"course organisation. Alzheimer's Research and Therapy, 2020, 12, 18.	3.0	0
85	Automated voxel- and region-based analysis of gray matter and cerebrospinal fluid space in primary dementia disorders. Brain Research, 2020, 1739, 146800.	1.1	7
86	Thalamic Deep Brain Stimulation for tremor: The critical role of intraoperative testing. Parkinsonism and Related Disorders, 2020, 73, 45-49.	1.1	5
87	Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome. Cerebellum, 2021, 20, 300-305.	1.4	8
88	Predicting the Prognosis of MCI Patients Using Longitudinal MRI Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 1164-1173.	1.9	15
89	Neuropsychological impact of white matter hyperintensities in older adults without dementia. Applied Neuropsychology Adult, 2021, 28, 354-362.	0.7	3
91	Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism. Neurotherapeutics, 2021, 18, 753-771.	2.1	3
92	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. European Radiology, 2021, 31, 5312-5323.	2.3	19
93	Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. Frontiers in Oncology, 2020, 10, 573512.	1.3	1
94	The neuroimaging of neurodegenerative and vascular disease in the secondary prevention of cognitive decline. Neural Regeneration Research, 2021, 16, 1490.	1.6	2
95	Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility. Advances in Experimental Medicine and Biology, 2021, 1281, 93-112.	0.8	5

#	ARTICLE	IF	CITATIONS
96	AD Resemblance Atrophy Index as a Diagnostic Biomarker for Alzheimer's Disease: A Retrospective Clinical and Biological Validation. Journal of Alzheimer's Disease, 2021, 79, 1023-1032.	1.2	14
97	Different patterns of gray matter atrophy in behavioral variant frontotemporal dementia with and without episodic memory impairment. International Journal of Geriatric Psychiatry, 2021, 36, 1848-1857.	1.3	7
98	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	2.8	12
99	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. Brain, 2021, 144, 2946-2953.	3.7	46
100	Molecular and Anatomical Imaging of Dementia With Lewy Bodies and Frontotemporal Lobar Degeneration. Seminars in Nuclear Medicine, 2021, 51, 264-274.	2.5	7
101	A longitudinal observation of brain structure between AD and FTLD. Clinical Neurology and Neurosurgery, 2021, 205, 106604.	0.6	5
102	Diagnosis of Dementia with Lewy Bodies: Fluctuations, Biomarkers, and beyond. , 0, , .		2
103	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. Neurology, 2021, 97, e814-e824.	1.5	14
104	An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis. Acta Neurologica Scandinavica, 2021, 144, 640-646.	1.0	2
105	Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents. Molecular Diversity, 2021, 25, 1517-1539.	2.1	8
106	Automatic quality control of brain T1-weighted magnetic resonance images for a clinical data warehouse. Medical Image Analysis, 2022, 75, 102219.	7.0	17
107	Potential markers for sample size estimations in hereditary spastic paraplegia type 5. Orphanet Journal of Rare Diseases, 2021, 16, 391.	1.2	2
108	Transient epileptic amnesia is significantly associated with discrete CA1-located hippocampal calcifications but not with atrophic changes on brain imaging. Epilepsy Research, 2021, 176, 106736.	0.8	1
109	Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities. Journal of Neurology, 2021, , 1.	1.8	7
110	Evaluation of MR Visual Rating Scales in Major Forms of Dementia. Journal of Neurosciences in Rural Practice, 2021, 12, 16-23.	0.3	13
111	Abnormal global functional network connectivity and its relationship to medial temporal atrophy in patients with amnestic mild cognitive impairment. PLoS ONE, 2017, 12, e0179823.	1.1	13
112	Six Visual Rating Scales as A Biomarker for Monitoring Atrophied Brain Volume in Parkinson's Disease. , 2020, 11, 1082.		7
113	Hippocampo-Horn Percentage and Parietal Atrophy Score for Easy Visual Assessment of Brain Atrophy on Magnetic Resonance Imaging in Early- and Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1259-1266.	1.2	5

#	ARTICLE	IF	CITATIONS
114	Possible Biomarkers for Frontotemporal Dementia and to Differentiate from Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Neuromethods, 2022, , 387-403.	0.2	0
115	Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Current Alzheimer Research, 2021, 18, 523-532.	0.7	6
116	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls. Frontiers in Aging Neuroscience, 2021, 13, 746982.	1.7	12
117	Voxel-Based Morphometry in Frontotemporal Dementia. Human Physiology, 2020, 46, 912-920.	0.1	0
118	Predicting Neural Deterioration in Patients with Alzheimer's Disease Using a Convolutional Neural Network. , 2020, , .		1
119	Brain atrophy patterns in patients with frontotemporal dementia: voxel-based morphometry. Bulletin of Russian State Medical University, 2020, , .	0.3	1
120	Modified Visual Magnetic Resonance Scale and Neuropsychometric Corelations in Alzheimer's disease. Anadolu KliniÄŸi TÄ±p Bilimleri Dergisi, 0, , .	0.1	0
121	Nuclear Imaging in Frontotemporal Dementia. , 2021, , 469-490.		0
122	Medial Temporal Atrophy Alone is Insufficient to Predict Underlying Alzheimer's Disease Pathology. Korean Journal of Family Medicine, 2020, 41, 352-358.	0.4	2
123	Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid β, an Alzheimer's disease pathology. Aging, 2020, 12, 19701-19710.	1.4	0
124	The Effect of Spinal Cord Injury on Beta-Amyloid Plaque Pathology in TgCRND8 Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 576-586.	0.7	2
125	The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale. Current Alzheimer Research, 2020, 17, 534-539.	0.7	6
126	Dementia with Lewy Bodies. , 2022, , 291-301.		0
127	Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2021, 121, 6.	0.1	31
128	Concordance of regional hypoperfusion by pCASL MRI and 15O-water PET in frontotemporal dementia: Is pCASL an efficacious alternative?. NeuroImage: Clinical, 2022, 33, 102950.	1.4	6
129	Characteristics of Cortical Atrophy and White Matter Lesions Between Dementia With Lewy Bodies and Alzheimer's Disease: A Case-Control Study. Frontiers in Neurology, 2021, 12, 779344.	1.1	6
130	Long COVIDâ€19: Objectifying most selfâ€reported neurological symptoms. Annals of Clinical and Translational Neurology, 2022, 9, 141-154.	1.7	67
131	Aetiology and pathophysiology of neurodegenerative disorders. , 2022, , 1-16.		0

#	Article	IF	Citations
132	Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study. Alzheimer's Research and Therapy, 2022, 14, 35.	3.0	22
133	Evaluation of brain atrophy using visual rating scales and their clinical contribution to the early and differential diagnosis of dementia. Neurologie Pro Praxi, 2021, 22, 358-374.	0.0	1
134	Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE. Alzheimer's Research and Therapy, 2021, 13, 193.	3.0	22
137	Functional Imaging for Neurodegenerative Diseases. Presse Medicale, 2022, 51, 104121.	0.8	3
138	Disentangling Reversal-learning Impairments in Frontotemporal Dementia and Alzheimer Disease. Cognitive and Behavioral Neurology, 2022, Publish Ahead of Print, .	0.5	1
139	Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy. Neurobiology of Aging, 2022, 117, 1-11.	1.5	6
140	Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects. Revue Neurologique, 2022, 178, 472-483.	0.6	2
141	Recent Advances in Frontotemporal Dementia. Canadian Journal of Neurological Sciences, 2023, 50, 485-494.	0.3	2
142	Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 6371.	1.8	10
143	Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment. Journal of Clinical Medicine, 2022, 11, 3433.	1.0	3
144	Diagnostic accuracy study of automated stratification of Alzheimer's disease and mild cognitive impairment via deep learning based on MRI. Annals of Translational Medicine, 2022, 10, 765-765.	0.7	4
145	GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer's disease and frontotemporal dementia using genetic algorithms. Medical and Biological Engineering and Computing, 2022, 60, 2737-2756.	1.6	12
146	Combined Score of Perivascular Space Dilatation and White Matter Hyperintensities in Patients with Normal Cognition, Mild Cognitive Impairment, and Dementia. Medicina (Lithuania), 2022, 58, 887.	0.8	5
147	Associations of multiple visual rating scales based on structural magnetic resonance imaging with disease severity and cerebrospinal fluid biomarkers in patients with Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
148	Brain atrophy pattern in patients with mild cognitive impairment: MRI study. Translational Neuroscience, 2022, 13, 335-348.	0.7	0
149	Early-stage differentiation between Alzheimer's disease and frontotemporal lobe degeneration: Clinical, neuropsychology, and neuroimaging features. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
150	Clinical Presentation, Diagnosis, and Pathogenesis of Dementia With Lewy Bodies. Psychiatric Annals, 2022, 52, 398-403.	0.1	0
151	Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design. Alzheimer's and Dementia, 2023, 19, 318-332.	0.4	15

#	ARTICLE	IF	CITATIONS
152	Magnetic resonance imaging in Parkinson's disease with mild cognitive impairment, Parkinson's disease dementia, and dementia with Lewy bodies. , 2023, , 297-307.		0
153	Diverse limbic comorbidities cause limbic and temporal atrophy in lewy body disease. Parkinsonism and Related Disorders, 2022, 105, 52-57.	1.1	3
154	Diencephalic versus Hippocampal Amnesia in Alzheimer's Disease: The Possible Confabulation-Misidentification Phenotype. Journal of Alzheimer's Disease, 2023, 91, 363-388.	1.2	1
155	Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes. Clinical and Translational Discovery, 2023, 3, .	0.2	3
156	Young-onset dementia diagnosis, management and care: a narrative review. Medical Journal of Australia, 2023, 218, 182-189.	0.8	12
157	A discriminative event-based model for subtype diagnosis of sporadic Creutzfeldt-Jakob disease using brain MRI. Alzheimer's and Dementia, 2023, 19, 3261-3271.	0.4	2
158	Combining semi-quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?. Neuroradiology, 0, , .	1.1	0
159	Visual atrophy rating scales and amyloid <scp>PET</scp> status in an Alzheimer's disease clinical cohort. Annals of Clinical and Translational Neurology, 2023, 10, 619-631.	1.7	2
160	Voxel-Based and Surface-Based Morphometry Analysis in Patients with Pathologically Confirmed Argyrophilic Grain Disease and Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 93, 379-387.	1.2	4
163	Radiologie van hoofd en hersenen. , 2023, , 49-72.		0
166	The use of neuroimaging techniques in the early and differential diagnosis of dementia. Molecular Psychiatry, 2023, 28, 4084-4097.	4.1	2